Biond Biologics Announces Initiation of a Phase 2 Study of BND-22 in Combination with anti-PD-1 therapy
Trial will identify response and predictive biomarkers for the combination of BND-22, a first-in-class anti-ILT2 antibody with anti-PD1 therapy MISGAV,...